




Providing impact for solid cancer patients with next generation T cell therapies


Pan Cancer T
Rachel Abbott, CEO




Current treatments for Triple Negative Breast Cancer (TNBC) are failing



1 in 7 women develop breast cancer




Up to 20% of breast cancer cases are TNBC (135.000 women/year*)



Median survival <6 months once TNBC is metastatic

Our lead product offers a promising novel therapy

Our technology empowers a patient's own immune system to kill cancer cells



Reprogramming T cells to fight cancer

Past decade has highlighted potential of adoptive cell therapy to cure cancer



Emily Whitehead

- Early blood cancer patients remain cancer-free >10 years after single treatment
- 7 FDA-approved T cell therapies for blood cancers




- Two T cell therapies have been approved in 2024 for solid cancers (melanoma and synovial sarcoma)




Several key challenges have limited the impact of adoptive cell therapy in TNBC and other solid cancers



Lack of suitable cancer-specific targets, limiting eligible patient populations



Requirement for novel cancer-specific receptors to genetically reprogram T cells




Limited sustained clinical responses due to immune suppression in the hostile tumour microenvironment


Our unique platform resolves challenges of adoptive cell therapy



Portfolio of first-in-class, tumour-restricted targets, robustly expressed in multiple hard-to-treat solid cancers (including TNBC)



TCR-T cells engineered with proprietary, cancer-specific T cell receptors (TCRs) that optimally recognise our targets



Next generation T cells engineered to overcome immune suppression in the tumour microenvironment and improve response durability

Combined output from these platforms has led to development of PCT1:CO-STIM, our lead clinical candidate for TNBC




ROPN1 is a unique, novel tumor target in >90% TNBC and melanoma patients



- No ROPN1 expression in normal healthy tissue:




- But strong cancer-specific expression in:



Our TCR discovery platform generated PCT1: a highly specific receptor against ROPN1



PCT1 TCR-T cells are highly efficacious and outperform TNBC standard of care drug




- **PCT1 TCR-T** destroy TNBC tumours, significantly outperforming TNBC standard-of-care treatment **Sacituzumab govitecan**

Our TCR:CO-STIM technology offers unique solution to enhance durability of response



TCR:CO-STIM provides co-stimulation even in the hostile tumour microenvironment



- **TCR:CO-STIM** extends duration of anti-tumour response

Seeking €30M to generate clinical efficacy data with lead asset in TNBC and to advance pipeline

	Target	Indication	Discovery	Preclinical	Clinical Development
Lead Product	ROPN1	TNBC, Melanoma	PCT1:CO-STIM		
T Cell Receptor Discovery	To be disclosed	Pan cancer	PCT6		
	To be disclosed	Ovarian	PCT10		
Tumour Microenvironment Solutions	To be disclosed	Pan cancer	TCR:CO-STIM Platform		
	To be disclosed	Pan cancer	TME2		

} Programs available for partnering

TCR-T cell therapy is an exciting field that is gaining momentum

November 15, 2023 05:46 AM EST Updated 07:08 AM | Financing, Startups



Sanofi-backed T-Therapeutics bags \$59M in Series A to unlock potential of TCR therapeutics: #Jefferies23

BIOTECH

Galapagos selects Adaptimmune T-cell therapy for \$665M biobucks collab

By Annalee Armstrong · May 31, 2024 9:40am

UPDATE: Bristol Myers triples-down on Immutics, bringing deal to \$4.2B total biobucks. Why not just buy it?

By Annalee Armstrong · Jun 2, 2022 11:48am

Moderna, Immutics ink \$120m cancer-focused partnership

by Millie Nelson

Wednesday, September 13, 2023 4:48 am

The multi-platform cancer-focused partnership will see Moderna combine its mRNA technology with Immutics' TCR platform.

Pharmaceutical
Technology


News | November 29, 2022

AstraZeneca enters \$320m deal to acquire Neogene

We offer a unique DUAL approach



Additional Engineering
to improve response durability



Our team has deep experience spanning all aspects of taking TCR-T cell therapies to the clinic

Management Team



Rachel Abbott
CEO



Dora Hammerl
VP R&D



Reinout Hesselink
VP Process Development



Tom Holdich
CMO



Lars Ottevanger
VP Finance



Marcel Zwaal
Business Development



Supervisory Board



John Tchelingirian
The Connecting Architects
Silver Ocean Ventures



Dharminder Chahal
Van Herk Investments
Swanbridge Capital



Chris Bangma
Erasmus MC



Michel Briejer
Thuja Capital

Scientific Advisory Board




Chiara Bonini
Università Vita-Salute
San Raffaele



Reno Debets
Co-founder
Erasmus MC



David Gilham
Executive Scientific
Advisor



Neil Sheppard
University of
Pennsylvania



Hans Stauss
University College
London



Henk Verheul
Erasmus MC



Thank You!

Rachel Abbott, CEO

rachel.abbott@pancancer-t.com

